← Back to all trials
Completed
NCT07487701
Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study
Conditions: Migraine
Sex: All
Ages: 8 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 332
Sponsor: Theranica
Location: Theranica Bio-Electronics Inc Bridgewater New Jersey
Summary
Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited. Remote electrical neuromodulation (REN) is a non-invasive FDA-cleared wearable device for acute and/or preventive migraine treatment. This study will evaluate the real-world efficacy and patient-reported outcomes of preventive REN use over 3 months in migraine patients.
Eligibility Criteria
Inclusion Criteria:
* Patient with migraine
* Prescribed with a Nerivio REN device
* Treat with nerivio in a preventive -like manner over 3 consecutive months from sign up.
Exclusion Criteria:
* NA
Source: ClinicalTrials.gov (NCT07487701). StuddyBuddy aggregates publicly available trial information.
